CME

Faculty: Chee Kay Cheung, MBChB, MRCP, PhD

Faculty: Jörg Latus, MD

This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN therapies, critically evaluating how each targets specific disease pathways—such as galactose-deficient IgA1 formation, complement activation, and podocyte injury. Second, the program presents a systematic diagnostic approach for confirming suspected IgAN, covering clinical presentation, laboratory workup, urinary biomarkers, and renal biopsy interpretation. Third, participants will evaluate the potential benefits and risks of novel therapies aimed at clinically meaningful proteinuria reduction—including efficacy data, safety considerations, and real-world applicability. Finally, the activity guides clinicians in developing optimized, evidence-based treatment plans that incorporate novel proteinuria-lowering therapies within the broader context of individualized disease management, aligned with current guideline recommendations and patient comorbidities.

Faculty: Jonathan Barratt, MD, PhD

Faculty: Jörg Latus, MD

This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN therapies, critically evaluating how each targets specific disease pathways—such as galactose-deficient IgA1 formation, complement activation, and podocyte injury. Second, the program presents a systematic diagnostic approach for confirming suspected IgAN, covering clinical presentation, laboratory workup, urinary biomarkers, and renal biopsy interpretation. Third, participants will evaluate the potential benefits and risks of novel therapies aimed at clinically meaningful proteinuria reduction—including efficacy data, safety considerations, and real-world applicability. Finally, the activity guides clinicians in developing optimized, evidence-based treatment plans that incorporate novel proteinuria-lowering therapies within the broader context of individualized disease management, aligned with current guideline recommendations and patient comorbidities.

Faculty: Chee Kay Cheung, MBChB, MRCP, PhD

This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN therapies, critically evaluating how each targets specific disease pathways—such as galactose-deficient IgA1 formation, complement activation, and podocyte injury. Second, the program presents a systematic diagnostic approach for confirming suspected IgAN, covering clinical presentation, laboratory workup, urinary biomarkers, and renal biopsy interpretation. Third, participants will evaluate the potential benefits and risks of novel therapies aimed at clinically meaningful proteinuria reduction—including efficacy data, safety considerations, and real-world applicability. Finally, the activity guides clinicians in developing optimized, evidence-based treatment plans that incorporate novel proteinuria-lowering therapies within the broader context of individualized disease management, aligned with current guideline recommendations and patient comorbidities.

Faculty: Chee Kay Cheung, MBChB, MRCP, PhD

Faculty: An De Vriese, MD, PhD

Faculty: Jörg Latus, MD

This comprehensive educational activity focuses on 4 key dimensions of IgA nephropathy (IgAN) management. First, attendees will compare and contrast the mechanisms of action (MOAs) of both approved and investigational IgAN therapies, critically evaluating how each targets specific disease pathways—such as galactose-deficient IgA1 formation, complement activation, and podocyte injury. Second, the program presents a systematic diagnostic approach for confirming suspected IgAN, covering clinical presentation, laboratory workup, urinary biomarkers, and renal biopsy interpretation. Third, participants will evaluate the potential benefits and risks of novel therapies aimed at clinically meaningful proteinuria reduction—including efficacy data, safety considerations, and real-world applicability. Finally, the activity guides clinicians in developing optimized, evidence-based treatment plans that incorporate novel proteinuria-lowering therapies within the broader context of individualized disease management, aligned with current guideline recommendations and patient comorbidities.

Faculty: Komal Jhaveri, MD, FACP

Hear an expert discussion between Dr. Komal Jhaveri and Dr. Virginia Kaklamani as they examine the evolving role of oral selective estrogen receptor degraders (SERDs), including PROTACs and novel combination strategies, in the treatment of ER+/HER2− metastatic breast cancer. Drs. Jhaveri and Kaklamani review emerging efficacy and safety data, considerations for treatment selection after prior endocrine therapy and CDK4/6 inhibitor exposure, the role of ESR1 mutation testing in sequencing therapy, and emerging combination and frontline treatment data. The discussion also highlights practical, interdisciplinary approaches to monitoring and managing adverse events to support evidence-based clinical decision-making in practice.

Update: On September 4, 2026, the FDA granted accelerated approval to camizestrant in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK 4/6 inhibitor therapy, based on an FDA-authorized test.

Update: On September 18, 2026, the FDA approved imlunestrant in combination with abemaciclib, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an …

Chair: Komal Jhaveri, MD, FACP

Faculty: Virginia Kaklamani, MD, DSc

Hear an expert discussion between Dr. Komal Jhaveri and Dr. Virginia Kaklamani as they examine the evolving role of oral selective estrogen receptor degraders (SERDs), including PROTACs and novel combination strategies, in the treatment of ER+/HER2− metastatic breast cancer. Drs. Jhaveri and Kaklamani review emerging efficacy and safety data, considerations for treatment selection after prior endocrine therapy and CDK4/6 inhibitor exposure, the role of ESR1 mutation testing in sequencing therapy, and emerging combination and frontline treatment data. The discussion also highlights practical, interdisciplinary approaches to monitoring and managing adverse events to support evidence-based clinical decision-making in practice.

Update: On September 4, 2026, the FDA granted accelerated approval to camizestrant in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK 4/6 inhibitor therapy, based on an FDA-authorized test.

Update: On September 18, 2026, the FDA approved imlunestrant in combination with abemaciclib, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an …

Chair: Komal Jhaveri, MD, FACP

Faculty: Virginia Kaklamani, MD, DSc

Hear an expert discussion between Dr. Komal Jhaveri and Dr. Virginia Kaklamani as they examine the evolving role of oral selective estrogen receptor degraders (SERDs), including PROTACs and novel combination strategies, in the treatment of ER+/HER2− metastatic breast cancer. Drs. Jhaveri and Kaklamani review emerging efficacy and safety data, considerations for treatment selection after prior endocrine therapy and CDK4/6 inhibitor exposure, the role of ESR1 mutation testing in sequencing therapy, and emerging combination and frontline treatment data. The discussion also highlights practical, interdisciplinary approaches to monitoring and managing adverse events to support evidence-based clinical decision-making in practice.

Update: On September 4, 2026, the FDA granted accelerated approval to camizestrant in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK 4/6 inhibitor therapy, based on an FDA-authorized test.

Update: On September 18, 2026, the FDA approved imlunestrant in combination with abemaciclib, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an …

Faculty: Virginia Kaklamani, MD, DSc

Hear an expert discussion between Dr. Komal Jhaveri and Dr. Virginia Kaklamani as they examine the evolving role of oral selective estrogen receptor degraders (SERDs), including PROTACs and novel combination strategies, in the treatment of ER+/HER2− metastatic breast cancer. Drs. Jhaveri and Kaklamani review emerging efficacy and safety data, considerations for treatment selection after prior endocrine therapy and CDK4/6 inhibitor exposure, the role of ESR1 mutation testing in sequencing therapy, and emerging combination and frontline treatment data. The discussion also highlights practical, interdisciplinary approaches to monitoring and managing adverse events to support evidence-based clinical decision-making in practice.

Update: On September 4, 2026, the FDA granted accelerated approval to camizestrant in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK 4/6 inhibitor therapy, based on an FDA-authorized test.

Update: On September 18, 2026, the FDA approved imlunestrant in combination with abemaciclib, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an …

Faculty: Gianluigi Savarese, MD, PhD, FESC, FHFA

In this Patient-Clinician Connection, Dr. Gianluigi Savarese uses a clinical case to demonstrate shared decision-making strategies for managing chronic and recurrent hyperkalemia in patients with chronic kidney disease and heart failure receiving guideline-directed medical therapy (GDMT). The discussion examines how to address patient concerns about hyperkalemia while supporting the continued use of evidence-based therapies that improve cardiovascular outcomes. Practical considerations for potassium management, including the role of oral potassium binders and individualized treatment planning, are also reviewed.

Chair: Rishi Singh, MD, FASRS

Faculty: Ferhina S. Ali, MD, MPH, FASRS

Faculty: Baruch D. Kuppermann, MD, PhD

Despite the well-known efficacy of anti-VEGF agents, a significant proportion of patients with DME or nAMD continue to show persistent or recurrent retinal fluid on OCT. This activity brings together expert faculty to discuss how to identify patients with VEGF-refractory disease and optimize management. Attendees will also gain insight into emerging therapeutic pathways, including Wnt, the angiopoietin (Ang)/Tie2 pathway, and tyrosine kinase inhibitors (TKIs), that may improve retinal vascular stability and treatment durability.